WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524115

CAS#: 181141-52-6; 186293-38-9 (ABT-255 free base);

Description: ABT-255 is a novel 2-pyridone antibacterial agent which demonstrates in vitro potency and in vivo efficacy against drug-susceptible and drug-resistant M. tuberculosis strains. It is used as therapy for pulmonary tuberculosis.

Price and Availability




ABT-255, purity > 98%, is not in stock, may be available through custom synthesis. Minimum 1 gram order is requested. Current shipping out time is about 70 days after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 524115
Name: ABT-255
CAS#: 181141-52-6; 186293-38-9 (ABT-255 free base);
Chemical Formula: C21H25ClFN3O3
Exact Mass:
Molecular Weight: 421.89
Elemental Analysis: C, 59.78; H, 5.97; Cl, 8.40; F, 4.50; N, 9.96; O, 11.38

Synonym: ABT-255; ABT 255; ABT255; UNII-YA04O24J4T;

IUPAC/Chemical Name: 1-cyclopropyl-7-fluoro-8-((4aS,7aS)-hexahydro-1H-pyrrolo[3,4-b]pyridin-6(2H)-yl)-9-methyl-4-oxo-4H-quinolizine-3-carboxylic acid hydrochloride


InChi Code: InChI=1S/C21H24FN3O3.ClH/c1-11-18-14(12-4-5-12)7-15(21(27)28)20(26)25(18)9-16(22)19(11)24-8-13-3-2-6-23-17(13)10-24;/h7,9,12-13,17,23H,2-6,8,10H2,1H3,(H,27,28);1H/t13-,17+;/m0./s1

SMILES Code: O=C(C1=CC(C2CC2)=C3C(C)=C(N(C4)C[C@]5([H])[C@@]4([H])CCCN5)C(F)=CN3C1=O)O.[H]Cl

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Segreti JA, Polakowski JS, Koch KA, Marsh KC, Bauch JL, Rosenberg SH, Sham HL, Cox BF, Reinhart GA. Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol. 2004 Sep;54(3):273-81. Epub 2004 Jun 2. PubMed PMID: 15173957.

2: Tomioka H. [Prospects for development of new antituberculous drugs]. Kekkaku. 2002 Aug;77(8):573-84. Japanese. PubMed PMID: 12235850.

3: Oleksijew A, Meulbroek J, Ewing P, Jarvis K, Mitten M, Paige L, Tovcimak A, Nukkula M, Chu D, Alder JD. In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother. 1998 Oct;42(10):2674-7. PubMed PMID: 9756775; PubMed Central PMCID: PMC105917.